NASDAQ: INVAInnoviva Inc Stock Ownership - Who owns Innoviva?
Insider buying vs selling
Have Innoviva Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Marianne Zhen | Chief Accounting Officer | 2024-11-20 | 976 | $19.15 | $18.69kSell |
| Marianne Zhen | Chief Accounting Officer | 2024-08-20 | 975 | $18.49 | $18.03kSell |
| Matthew Ronsheim | Officer | 2024-05-20 | 268 | $16.13 | $4.32kSell |
| Marianne Zhen | Chief Accounting Officer | 2024-05-20 | 976 | $16.13 | $15.74kSell |
| Stephen Basso | Chief Financial Officer | 2024-03-05 | 12,096 | $14.88 | $179.99kBuy |
| Matthew Ronsheim | Officer | 2024-03-05 | 12,768 | $14.88 | $189.99kBuy |
| Marianne Zhen | Chief Accounting Officer | 2024-03-05 | 10,752 | $14.88 | $159.99kBuy |
| Marianne Zhen | Chief Accounting Officer | 2024-02-20 | 2,862 | $15.80 | $45.22kSell |
| Matthew Ronsheim | Officer | 2024-02-20 | 807 | $15.80 | $12.75kSell |
| Matthew Ronsheim | Officer | 2024-01-18 | 1,600 | $16.05 | $25.68kSell |
INVA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when INVA insiders and whales buy or sell their stock.
INVA Shareholders
What type of owners hold Innoviva Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Glaxosmithkline PLC | 51.13% | 32,005,260 | $607.78M | Insider |
| Blackrock Inc 1 | 15.06% | 9,424,849 | $178.98M | Institution |
| Sarissa Capital Management LP | 11.62% | 7,277,000 | $138.19M | Institution |
| Alexander J. Denner | 11.62% | 7,277,000 | $138.19M | Insider |
| Franklin Resources Inc | 10.77% | 6,745,045 | $128.09M | Institution |
| Vanguard Group Inc | 9.95% | 6,227,697 | $118.26M | Institution |
| Dimensional Fund Advisors LP | 7.50% | 4,692,926 | $89.12M | Institution |
| Renaissance Technologies LLC | 6.92% | 4,329,907 | $82.22M | Institution |
| Jeffrey M. Drazan | 4.62% | 2,893,921 | $54.96M | Insider |
| Pacer Advisors Inc | 4.49% | 2,810,951 | $53.38M | Institution |
INVA vs Biotech Stocks
Innoviva Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.